Luo Lin-zhi, Xu Ling
Department of Scientific Research, PUMC Hospital, CAMS, PUMC, Beijing 100730, China.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2003 Jun;25(3):346-9.
There is a closely relationship between vitamin K and osteoporosis. As a cofactor for carboxylase activity, vitamin K can facilitate the conversion of glutamyl to gamma-carboxyglutamyl residues and influence the synthesis and excretion of gamma-carboxylation of osteocalcin to increase the formation of bone. Vitamin K can also effectively inhibit the absorption of bone mass. Besides, there are increasing evidences that vitamin K can effect the synthesis and excretion of nephrocalcin and interlukin-1,6 that can regulate calcium balance and bone metabolism. Meanwhile, there is a consistent line of evidence in human epidemiologic and intervention studies that clearly demonstrate that vitamin K can not only increase bone mineral density in osteoporotic people, but also reduce fracture rates to improve bony health. However more researches are required before vitamin K is widely applied in prevention and treatment of osteoporosis. The American Medical Association recently has increased the dietary reference intakes of vitamin K to 90 mg/d for females and 120 mg/d for males.
维生素K与骨质疏松症之间存在密切关系。作为羧化酶活性的辅助因子,维生素K可促进谷氨酰基向γ-羧基谷氨酰基残基的转化,并影响骨钙素γ-羧化的合成与排泄,以增加骨的形成。维生素K还能有效抑制骨质吸收。此外,越来越多的证据表明,维生素K可影响肾钙素和白细胞介素-1、6的合成与排泄,而它们能够调节钙平衡和骨代谢。同时,人体流行病学和干预研究中有一系列连贯的证据清楚地表明,维生素K不仅可以提高骨质疏松症患者的骨密度,还能降低骨折率,改善骨骼健康。然而,在维生素K被广泛应用于骨质疏松症的预防和治疗之前,还需要更多的研究。美国医学协会最近将维生素K的膳食参考摄入量提高到女性90毫克/天,男性120毫克/天。